New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

Andreas Kjaer; Morten Persson; Michael Ploug

New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

Andreas Kjaer (Inventor), Morten Persson (Inventor), Michael Ploug (Inventor)

Endocrinology and Metabolism

Abstract

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

Original language	English
IPC	C07K 16/ 30 A I
Patent number	CN104768573
Country/Territory	Denmark
Priority date	03/05/2013
Priority number	WO2013DK50126
Publication status	Published - 8 Jul 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Fingerprint

Dive into the research topics of 'New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors'. Together they form a unique fingerprint.

Cite this

New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. / Kjaer, Andreas (Inventor); Persson, Morten (Inventor); Ploug, Michael (Inventor).

Patent No.: CN104768573. Jul 08, 2015.

Research output: Patent

@misc{8f7e108f24f948819f2b98736f69b76d,

title = "New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors",

abstract = "There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.",

author = "Andreas Kjaer and Morten Persson and Michael Ploug",

year = "2015",

month = jul,

day = "8",

language = "English",

type = "Patent",

note = "CN104768573; C07K 16/ 30 A I",

}

TY - PAT

T1 - New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

AU - Kjaer, Andreas

AU - Persson, Morten

AU - Ploug, Michael

PY - 2015/7/8

Y1 - 2015/7/8

N2 - There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

AB - There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

M3 - Patent

M1 - CN104768573

ER -